JANEX-1 - CAS 202475-60-3
Catalog number: 202475-60-3
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C16H15N3O3
Molecular Weight:
297.31
COA:
Inquire
Targets:
JAK
Description:
A cell-permeable, reversible, potent, ATP-competitive, and specific inhibitor of JAK3 (Janus family kinase 3; IC50 = 78 µM). Has no effect on JAK1, JAK2, or Zap/Syk or Src tyrosine kinases. Acts as a potent inhibitor of glioblastoma cell adhesion and migration. Also reported to block thrombin-induced platelet aggregation.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
WHI-P131; Janex 1; WHI-P 131
MSDS:
Inquire
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related JAK Products


CAS 1092499-93-8 NVP-BSK805

NVP-BSK805
(CAS: 1092499-93-8)

NVP-BSK805, a quinoxaline derivative, is a selective ATP-competitive JAK2 inhibitor which could induce apoptosis (GI50 < 100 nM) and restrain the growth of JAK2...

CAS 935666-88-9 AZD-1480

AZD-1480
(CAS: 935666-88-9)

AZD1480 is an orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. AZD1480 inhibits JAK2 activation, leadin...

CAS 1206163-45-2 Solcitinib

Solcitinib
(CAS: 1206163-45-2)

Solcitinib, also known as GSK2586184 or GLPG0778, is a Janus kinase 1 (JAK1) inhibitor. Solcitinib may be potential useful for treatment of psoriasis, systemic ...

CAS 944118-01-8 Peficitinib

Peficitinib
(CAS: 944118-01-8)

Peficitinib, also known as ASP015K and JNJ-54781532, is a novel potent JAK inhibitor, which demonstrated potent efficacy in adjuvant-induced arthritis model in ...

CAS 1198300-79-6 Cerdulatinib

Cerdulatinib
(CAS: 1198300-79-6)

Cerdulatinib, also known as PRT2070 and PRT062070, is a novel, oral, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor. Cerdulatinib preferenti...

NS-018 hydrochloride
(CAS: 1239358-85-0)

The hydrochloride salt form of NS-018 which is a selective JAK2 as well as Src family tyrosine kinases inhibitor that could probably induce the apoptosis of tum...

NS-018
(CAS: 1239358-86-1)

NS-018, a selective JAK2 as well as Src family tyrosine kinases inhibitor that could probably induce the apoptosis of tumor cells. It is still under Phase I/II ...

CAS 1257704-57-6 CEP33779

CEP33779
(CAS: 1257704-57-6)

CEP-33779 is a highly selective, orally active, small-molecule inhibitor of JAK2. CEP-33779 induced regression of established colorectal tumors, reduced angioge...

CAS 944842-54-0 Decernotinib

Decernotinib
(CAS: 944842-54-0)

Decernotinib, also known as VX-509 or VRT-831509 or adelatinib, is an oral, selective Janus kinase 3 (JAK3) inhibitor being developed by Vertex. VX-509 may repr...

CAS 1092578-46-5 (3R,4S)-Tofacitinib

(3R,4S)-Tofacitinib
(CAS: 1092578-46-5)

Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.

CAS 937272-79-2 Pacritinib

Pacritinib
(CAS: 937272-79-2)

Pacritinib, also known as SB1518, is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic acti...

Upadacitinib
(CAS: 1310726-60-3)

Upadacitinib is a selective JAK inhibitor under the development of AbbVie.ABT-494 is nearly 74 fold selective for Jak1 over Jak2 in cellular assays dependent on...

CAS 80418-25-3 20(S)-Notoginsenoside R2

20(S)-Notoginsenoside R2
(CAS: 80418-25-3)

20(S)-Notoginsenoside R2 is a natural product extracted from the roots of Panax notoginseng (Burk.) F.H.Chen. It has neuroprotection against 6-OHDA-induced neur...

CP-690550A
(CAS: 1243290-37-0)

This active molecular is a novel Janus Kinase 3 (JAK3) inhibitor. CP-690550A is an immunosuppressant for the treatment of rheumatoid arthritis, psoriasis, trans...

CAS 1229236-86-5 LY2784544

LY2784544
(CAS: 1229236-86-5)

Gandotinib is a potent and selective JAK inhibitor, which effectively inhibited JAK2V617F-driven signaling and cell proliferation in Ba/F3 cells (IC50=20 and 55...

CAS 1092939-17-7 Ruxolitinib phosphate

Ruxolitinib phosphate
(CAS: 1092939-17-7)

Ruxolitinib phosphate is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus J...

PF-956980
(CAS: 1262832-74-5)

PF-956980, a close analogue of Tofacitinib, is a JAK3-selective inhibitor used as an anti-inflammatory agent. Besides, some studies showed that PF-956980 striki...

CAS 211555-04-3 WHI-P154

WHI-P154
(CAS: 211555-04-3)

WHI-P154 is a JAK3 inhibitor with IC50 = 1.8 μM. WHI-P154 displays no activity at JAK1 or JAK2. WHI-P154 also Inhibits STAT1 activation, iNOS expression and N...

CAS 1208319-27-0 Oclacitinib maleate

Oclacitinib maleate
(CAS: 1208319-27-0)

Oclacitinib maleate was the first selective Janus kinase (JAK) inhibitor to be developed for dogs. Oclacitinib is most potent at inhibiting JAK1 (IC50=10 nM).

Chemical Structure

CAS 202475-60-3 JANEX-1

Quick Inquiry

Verification code

Featured Items